116.2 Discovery and Development of Novel M1 and M4 PAMs for the Treatment of Schizophrenia.

James Barrow will discuss the use of Catechol-O-Methyl Transferase inhibitors in various models of impaired episodic memory in mice.Data indicate that novel COMT inhibitors are consistent with previous data using tolcapone.Jen Pan will discuss efforts at the Broad Institute Stanley Center Therapeutics Team on a novel protein target of schizophrenia motivated by emerging genetics.We present the data on a large set of rare coding variants of CACNA1I that are derived from both schizophrenia and control subjects in a Swedish schizophrenia cohort.We discuss our current efforts in target validating and drug discovery within an academic setting.Carrie Jones will describe efforts at Vanderbilt to advance Muscarinic Cholinergic PAMs as therapy for cognitive disabilities.This presentation will highlight the process of bringing a specific molecule from target discovery through the processes of molecular screening, compound optimization, preclinical testing and clinical development, all within an academic setting.The discussant, Matsuyuki Matsumoto, will then incorporate all these examples into an overview of how industry views and addresses collaboration with academia.